

PHARMACOLOGY
BIOCHEMISTRY
AND
BEHAVIOR

VOLUME 47, 1994
SUBJECT AND AUTHOR INDEX



PERGAMON

PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

US Editor-in-Chief

MATTHEW J. WAYNER

Division of Life Sciences, The University of Texas at San Antonio, San Antonio, TX 78249-0662

European Editor-in-Chief

SANDRA E. FILE

Psychopharmacology Research Unit, UMDS Division of Pharmacology, Guy's Hospital
P.O. Box 3448, London SE1 9QH, UK

Editorial Advisory Board

LIISA AHTEE, Helsinki, Finland
LEMBIT ALLIKMETS, Tartu, Estonia
ROBERT L. BALSTER, Richmond, VA
GIOVANNI BIGGIO, Cagliari, Italy
MIKE BRILEY, Castres, France
ALLAN C. COLLINS, Boulder, CO
DONALD V. COSCINA, Toronto, Ontario, Canada
JACQUELINE N. CRAWLEY, Bethesda, MD
ANNETTE DOMENEY, Geneva, Switzerland
ADRIAN J. DUNN, Shreveport, LA
BURR EICHELMAN, Philadelphia, PA
WILLIAM J. FREED, Washington, DC
RICHARD A. GLENNON, Richmond, VA
F. G. GRAEFF, São Paulo, Brazil
M. R. C. GREENWOOD, Davis, CA
ROLAND R. GRIFFITHS, Baltimore, MD
STEPHEN G. HOLTZMAN, Atlanta, GA
AKIRA HORITA, Seattle, WA
CHRIS E. JOHANSON, Baltimore, MD
HAROLD KALANT, Toronto, Ontario, Canada
G. JEAN KANT, Washington, DC
KATHLEEN M. KANTAK, Boston, MA

GEORGE F. KOOB, La Jolla, CA
CONAN KORNETSKY, Boston, MA
J. DAVID LEANDER, Indianapolis, IN
EMINY H. Y. LEE, Taipei, Taiwan
ALLEN S. LEVINE, Minneapolis, MN
WILLIAM J. McBRIDE, Indianapolis, IN
DONALD E. McMILLAN, Little Rock, AR
JACK H. MENDELSON, Belmont, MA
ROBERT D. MYERS, Greenville, NC
JUDITH A. PRATT, Glasgow, UK
ROSARIO SAMANIN, Milan, Italy
HERMAN H. SAMSON, Winston-Salem, NC
PAUL R. SANBERG, Tampa, FL
PHIL J. SKOLNICK, Bethesda, MD
CLARE STANFORD, London, UK
MARIE-HÉLÈNE THIÉBOT, Paris, France
DEREK VAN DER KOOY, Toronto, Ontario, Canada
JEANNE M. WEHNER, Boulder, CO
BRUNO E. WILL, Strasbourg, France
J. C. WINTER, Buffalo, NY
ALICE M. YOUNG, Detroit, MI
IAN S. ZAGON, Hershey, PA

PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

US Editorial Office:

Matthew J. Wayner

Division of Life Sciences, The University of Texas at San Antonio, 6900 North Loop 1604 West
San Antonio, TX 78249-0662
Fax: (210) 691-4510

European Editorial Office:

Sandra E. File

Psychopharmacology Research Unit, UMDS Division of Pharmacology, Guy's Hospital
P.O. Box 3448, London SE1 9QH, UK
Fax: 44-(0)71-955-4627

Production Editor:

Jonathan R. Goodnough

Publishing, Subscription, and Advertising Offices:

Elsevier Science Inc., 660 White Plains Road, Tarrytown, NY 10591-5153, USA, E-mail Address:
ESUK.USA@ELSEVIER.COM; and Elsevier Science Ltd, Headington Hill Hall, Oxford OX3 0BW, UK

Published Monthly

Annual Institutional Subscription Rates (1994): North, Central and South America, US\$1440.00, Rest of World £935.00. Associated Personal Subscription Rates are available on request for those whose institutions are library subscribers. Sterling prices exclude VAT. Non-VAT registered customers in the European Community will be charged the appropriate VAT in addition to the price listed. Prices include postage and insurance and are subject to change without notice.

Pharmacology Biochemistry and Behavior is an official journal of the International Behavioral Neuroscience Society. For information about the society, please contact: Dr. Linda Spear, Department of Psychology, State University of New York at Binghamton, Box 6000, Binghamton, NY 13902-6000, USA. Members of the International Behavioral Neuroscience Society may order personal subscriptions at a concessional rate; details of this rate are available upon request.



SUBJECT INDEX

- Abstinence, 107
 Activity, 409, 879
 Acute toxicity, 273
 Adrenergic receptor: α_2 , agonist, 171
 Age, 567
 Aggression, 753
 Aging, 41, 325
 Agonist, 701
 Agonistic behavior, 753
 AIT-082, 325
 Alcohol, 567, 625
 Alcohol consumption, 375
 Alcohol deprivation, 625
 Alcohol drinking, 385
 Alcohol preference, 345
 Allopregnanolone, 735
 α_1 -Adrenergic receptor, 989
 α_2 -Adrenergic heteroreceptors, 985
 α -Helical CRF, 393
 ALS, 901
 Aluminum, 587
 Alzheimer's disease, 41, 833
 Amantadine treatment, 451
 Ambulatory activity, 101
 Amino acids, 59, 493
 Amitriptyline, 21
 Amphetamine, 203, 345, 369, 413, 579, 803, 907, 963
 Analgesia, 177, 197
 Anesthesia: hypnosis, 171
 Anesthetic(s), 523, 721
 Angiotensin antagonist, 385
 Angiotensin receptor subtypes, 385
 Angiotensin II, 385
 Anhedonia, 761
 Animal model, 833
 Aniracetam, 219
 Anorectic activity, 701
 Anorexia, 59, 273, 865
 Anorexia nervosa, 215
 Antagonist, 701
 Anticipatory behaviour, 307
 Anticonflict effect, 873
 Anticonvulsant(s), 443, 839
 Antiemetics, 273
 Antinociception, 21, 727
 Anxiety, 183, 437, 459, 735
 Anxiolytic, 1
 AOAA, 5
 Apomorphine, 77
 APV, 493
 Area postrema, 363
 Arginine⁸-vasopressin, 27
 Aromatization, 183
 Arousal, 283
 Associative learning, 289

 AT₁ receptor, 385
 AT₂ receptor, 385
 Ataxia, 709
 Aversion, 659
 Aversiveness, 255

 Baboons, 981
 Backward conditioning, 547
 Barbiturate, 675
 Barrel rotation, 27
 Behavior, 13
 Behavioral satiety sequence, 307
 Behavioral sensitization, 161, 603, 989
 Behavioral test, 459
 Behavioral toxicology, 363
 Benzodiazepine(s), 437, 471, 739, 823
 Benzodiazepine receptor, 1, 681
 β -Blockers, 873
 β -Carbolines, 681, 689
 Bicuculline, 351
 Bipolar stimulation, 993
 Blood pressure, 187
 Body composition, 247
 Body temperature, 471
 Body weight, 255, 273, 427, 659, 865
 Brain level of β -carboline, 689
 Brainstem, 197
 Bromocryptine, 749
 Buprenorphine, 379
 Buspirone, 153, 947

 Ca²⁺, 355
 Caffeine, 89, 153, 919
 Calcium channels, 675, 757
 Cannabimimetic, 113
 Cannabinoid receptors, 33
 Cannabinoids, 47
 Caramiphen, 709
 Carbamazepine, 839
 Catalepsy, 509
 Catecholamines, 77, 935
 CCK-A receptor, 701
 CCK-B receptor, 701
 Central, 547
 C57BL/6, BALB/c, and DBA/2 mice, 375
 cFP-AAF-pAB, 715
 CGP 40116, 127
 CGRP, 121
 Channel blocker, 409
 Chlordiazepoxide, 153, 845, 947
 Chlorimipramine, 803
 Choice reaction performance, 219
 Cholecystokinin, 701
 Choline acetyltransferase activity, 833
 Chronic administration, 865
 Chronic drug administration, 427

 Chronic opioid, 379
 Chronic stress, 233, 789
 Chrysin, 1
 CI-966, 5
 Circadian, 65, 409
 Circadian rhythms, 471
³⁶Cl⁻ influx, 355
 Classical conditioning, 289, 523
 Clonidine, 215, 969
 Clozapine, 579
 CNS depression, 351
 Cocaine, 13, 203, 839, 981, 989, 997
 Cocaine addiction, 819
 Cocaine hydrochloride, 973
 Cocaine methiodide, 973
 Cocaine withdrawal, 451
 Cognitive, 41
 Cognitive changes, 901
 Cold stress, 935
 Concentric electrode, 993
 Concurrent acute exercise, 779
 Concurrent schedules, 107
 Conditioned taste aversion, 273, 363, 369, 547
 Continuous cocaine, 399
 Continuous cold-water swims, 727
 Convulsion, 689
 Copulation, 483
 Core body temperature, 65
 Core temperature, 27
 Cortical neurons, 355
 Corticosterone, 943, 947
 Corticotropin-releasing factor, 393
 Cosinor, 65
 Crickets, 493
 Critical period, 183
 CTOP, 715
 Cyclo(leucyl-glycyl) (CLG), 141

 D₁ receptor, 101, 369
 D₁ and D₂ receptors, 47
 D₂ antagonist, 77
 D₂ dopamine receptor, 141
 D₂ receptor, 101, 331, 369, 553
 DA₁ receptor, 749
 DA₂ receptor, 749
 DAMGO, 827
d-Amphetamine, 89
d,l-Amphetamine, 339
d- and *l*-fenfluramine, 541
 DAU 6215, 95
 Deficiency, 59
 Dehydroepiandrosterone, 437
 Dehydroepiandrosterone sulfate, 437
 Delta, 715
 δ^2 -Tetrahydrocannabinol, 47

- Denervation supersensitivity, 101
 Deoxynivalenol, 363
 Dependence, 675
 Depression, 985
 Descending pathway, 883
 Desensitization, 171
 Development, 889
 Dexfenfluramine, 307
 Dexmedetomidine, 171
 Dextromethorphan, 709
 Diazepam, 241, 739, 927, 947
 Dietary choice, 59
 Dietary intake, 187
 Dihydropyridine, 675
 Dihydroxyphenyl-tetrahydrothienopyridine (THP), 483
 Discrimination, 113, 317
 Discriminative stimulus, 743
 Dizocilpine, 443, 839
 Dizocilpine (MK-801), 603
 DOPAC, 47, 765
 Dopamine, 47, 77, 161, 331, 345, 369, 413, 509, 617, 749, 765, 803, 857, 907, 973
 Dopamine D₁ receptor, 483
 Dopamine receptor antagonists, 575
 Dopamine system, 819
 Dose-response analysis, 553
 Drinking, 207, 339
 Drinking behavior, 413, 633
 Drug abuse, 857
 Drug cue, 107
 Drug discriminability, 951
 Drug discrimination, 5, 153, 487, 575, 667, 743
 Drug effects, 59
 Drug self-administration, 13, 981
 D₃, 647
 DuP753, 385
 DuP 747, 487
 Dynorphin A(1-13), 421

 Eating, 207
 ECS-induced amnesia, 121
 Educated waveform, 65
 EEG, 283, 919
 8-OH-DPAT, 133, 301, 509, 947
 Ejaculation, 883
 Electrical stimulation, 993
 Electrically induced convulsions, 503
 Electroconvulsive shock, 477
 Electroconvulsive stimulation (ECS), 647
 Elevated plus-maze, 147, 183
 Elevated plus-maze test for anxiety, 591
 Enantiomers, 113
 Endopeptidase 24.15, 715
 Energy expenditure, 215
 Enkephalins, 771
 Epilepsy, 127
 Ethanol withdrawal, 443
 Ethanol, 147, 227, 345, 351, 355, 437, 547, 743, 795
 Eticlopride, 89, 907
 Excitatory amino acids, 443
 Exercise, 215
 Exploration, 427, 879
 Exploratory behaviour, 183, 591
 Extreme posture, 233

 Fawn-Hooded rat, 985
 Feeding, 215
 Feeding behavior, 59, 255
 Fenfluramine, 575

 FFA, 851
 Field study, 187
 5-HT, 307, 541
 5-HT receptors, 789
 5-HT_{1A} agonist, 133
 5-HT_{1A} receptor(s), 301, 873
 5-HT_{1C} receptors, 985
 5-HT₂ receptor, 301, 553, 667
 5-HT₃ receptor, 95, 399
 5-HTP, 547
 5-Hydroxytryptamine, 591, 803, 865, 883
 5-Hydroxytryptophan, 547
 Fixed-interval schedule, 997
 Flavor, 413
 Flesinoxan, 957
 Flumazenil, 681
 Fluoxetine, 575
 Food deprivation, 317, 969
 Food intake, 255, 427, 659, 851, 865
 Food reinforcement, 379
 Forced ambulation, 233
 Forebrain, 207
 Forward conditioning, 547
 4-Aminopyridine, 409
 FPL 14294, 701

 GABA, 5, 177, 351, 437
 GABA_A, 913
 GABA_A receptor, 177
 GABA/Bz receptor, 147
 GABA neuroactive steroids, 735
 GABA receptor complex, 355
 Genetic, 375
 Genetics, 721, 889
 Gerbils, 113
 Global ischemia, 963
 Glucoprivic feeding, 317
 Glucose metabolism, 833
 Glutamate, 907
 Glutamic acid, 351
 Glycine, 241
 Growth hormone, 985
 Guide cannula assembly, 993

 Habituation, 427
 Hallucinogens, 289, 667
 Haloperidol, 369, 553, 579, 633, 761, 963
 Handling, 765
 HAS, 721
 Head twitch, 301
 Heart rate, 27, 187, 295
 [³H]8-OH-DPAT binding, 667
 Hindbrain, 207
 Hippocampus, 833
 Histamine, 503
 [³H]Ketanserin binding, 667
 Horizontal movement, 827
 Hormones, 857
 HPLC, 255
 Human laboratory, 531
 Human satietin, 255
 HVA, 765
 Hyperactivity, 331
 Hyperalgesia, 197
 Hyperdipsia, 339
 Hypnosis, 567
 Hypnotics, 359
 Hypoalgesia, 227
 Hypophagia, 273
 Hypothermia, 567
 Hypoxia, 219

 Ibogaine, 13
 ICV administration, 121
 ICV infusion, 255
 Imbalance, 59
 Imipramine, 427
 Immunosuppression, 497
 Individual differences, 73
 Individual housing, 497
 Ingestion, 255
 Ingestive behaviors, 413
 Inhibitory avoidance, 951
 Insects, 493
 Insulin, 317
 Intact proestrous females, 467
 Intake, 133
 Interferon, 901
 Intermediate stage, 359
 Intermittent cocaine, 399
 Intermittent cold-water swims, 727
 Intracerebroventricular, 21
 Intracerebroventricular infusions, 973
 Intracerebroventricular injection(s), 587, 743
 Intracranial stimulation, 993
 Intranasal, 701
 Intraperitoneal injection, 587
 Intrathecal, 21, 177
 Intravenous, 21
 In vivo receptor binding, 553
 Ipsapirone, 957
 [¹²⁵I]R-DOI binding, 667
 Ischemia, 219
 Isolation distress, 735
 IV self-administration, 819

 Japanese quail, 77

 Kappa, 715
 Kappaergic, 197
 Kappa-opioid agonist, 575
 κ -Opioid analgesic, 487

 Lactate, 779
 Lactation, 857
 L-Amphetamine, 41
 LAS, 721
 Lateral hypothalamus, 247
 L-Deprenyl, 41
 Lead, 227
 Lean, 625
 Learning, 477, 523, 647, 681, 833
 LEK-8804, 301
 Lever press, 997
 L-Glutamate, 351
 Licking, 997
 Limbic forebrain, 33
 Limited access, 375
 Lisuride, 819
 Lithium, 73
 Lithium chloride, 547
 Locomotion, 427, 591, 879
 Locomotor activity, 603, 709, 827, 839, 907, 969
 Locus coeruleus, 171
 Long-term memory, 493
 Losartan, 385
 Loss of righting reflex, 351
 Lysergic acid diethylamide (LSD), 667

 Macronutrient selection, 273
 Male and female rats, 997
 Male sexual behavior, 77, 591

- MAO-A, 41
 MAO-B, 41
 Marijuana, 47, 113
 Masking, 153
 Matching-to-sample, 935
 Maternal, 927
 Maternal behavior, 857
 Maternal separation, 735
 mCPP, 541
 MDMA, 289, 369
 Meadow voles, 265
 Medial preoptic area, 483
 Medial vestibular nucleus, 739
 Memory, 283, 477
 Memory consolidation, 493
 Memory deficit, 325
 Mesolimbic, 331
 Metergoline, 307
 Methadone, 379
 Methamphetamine, 161, 219, 879
 Methamphetamine sensitization, 101
 Methcathinone, 981
 Methodology, 531
 Metoclopramide, 273
 Mice, 325, 437, 753, 839
 Microdialysis, 161, 765, 973
 Microinjection, 743
 Microwave exposure, 845
 Midazolam, 5
 Midbrain transection, 207
 MK212, 541
 MK-801, 127, 443, 907
 Molecular modeling, 667
 Monoamine oxidase, 41
 Morphine, 339, 421, 559, 633, 765, 969
 Morris water maze, 95, 265, 477
 Motor activity, 47, 437
 Motor behaviour, 127
 Motoric deficit, 761
 Mouse, 127, 219
 Mouse staircase test, 845
 Mu, 715
 μ -Opioid peptide agonist, 827
 μ_2 -Opioid receptor, 943
 Muscimol, 177
 Muscle and brain, 779

 Naloxone, 265, 493, 541
 Naltrexone, 559
 Naltrindole, 715
 NAN-190, 301, 957
 Narcolepsy, 65
 Nasal spray, 295
 Natural compound, 1
 Nausea, 273
 NCAM, 647
 Neonates, 857
 Neuroleptics, 141, 761
 Neuromodulation, 493
 Neuropeptide Y, 207
 Neurotoxicity, 901
 Nicotine, 197, 295, 331, 889, 919
 Nicotinic receptors, 889
 Nictitating membrane, 289
 Nictitating membrane response, 523
 Nigrostriatal, 331
 Nigrostriatal dopaminergic neurons, 47
 Nipple shifting, 133
N-Isopropyl lysergamides, 667
 Nitric oxide, 727
 Nitrous oxide, 523
 NMDA, 493
 NMDA antagonist, 127
 NMDA receptor antagonists, 823
 NMDA receptors, 907
Nⁿ-Nitro-L-arginine, 727
 NO, 493
 Nociception, 177, 197
 Nonassociative learning, 289
 Nonopioid, 727
 Nootropic drug, 283
 Nor-binaltorphimine, 715
 (–)-Norpseudoephedrine, 339
 NS-3, 477
 Nucleus accumbens, 345, 765

 Obese, 625
 Octapeptide, 701
 Office vs. nonoffice work, 187
 Ondansetron, 59, 633
 Ontogeny, 133, 161, 927
 Open-field, 113, 459
 Operant, 113
 Operant behavior, 559
 Operant responding, 515
 Opiate agent, 789
 Opiates, 265
 Opioid(s), 197, 493, 715, 727, 927
 Opioid antagonists, 559
 Opioid peptides, 421
 Organ growth, 247
 Oxiracetam, 283
 Oxytocin, 273

 Pain, 21, 177
 Palatability, 73, 307, 413
 Paradoxical sleep, 359
 Parkinson's disease, 41
 Passive avoidance behaviour, 121
 Passive avoidance memory, 587
 p-Chloramphetamine, 803
 PCP, 579
 PCPA, 957
 PD123319, 385
 Pentobarbital, 5, 879
 Pentyleneetetrazol, 241
 Pentylenetetrazole-induced convulsions, 503
 Peripheral, 547
 Pharmacogenetics, 443
 Pharmacology, 59
 Phencyclidine (PCP), 603, 709
 Phenobarbital, 951
 Phenytoin, 951
 Phosphoinositide hydrolysis, 989
 Physical activity, 187
 Physiology, 59
 Physostigmine, 325, 779
 Pica, 273
 Pigeons, 113
 Pimozide, 515
 Pindolol, 957
 Place conditioning, 973
 Place preference, 771, 907
 Plasma, 779
 Plasma substrates, 247
 Potassium, 409
 Prazosin, 851
 Preference, 625, 795
 Pregnancy, 857
 Pregnanolones, 177
 Preoptic area, 77
 Prewatering, 761
 Procaine hydrochloride, 973

 Proceptivity, 467
 Procognitive drugs, 757
 Progesterone, 177
 Progestins, 177
 Progressive ratio, 379
 Prolactin, 857
 Protein malnutrition, 789
 Psychedelics, 289
 Psychomotor stimulants, 981
 Purine, 325
 Pygmy goats, 851
 Pyruvate, 779

 Quinine, 73, 413
 Quinpirole, 89

 Rabbit, 289, 523
 Raclopride, 369, 509, 753
 Radial arm maze, 963
 Radial maze, 283
 Rat(s), 21, 41, 59, 147, 219, 233, 241, 307, 317, 359, 363, 379, 393, 399, 427, 451, 459, 509, 515, 541, 721, 735, 757, 761, 795, 865, 907, 957, 969, 973, 989
 Rat behavior, 587
 Rat fetus, 715
 Rat pups, 947
 Rearing, 827
 Receptivity, 467
 Receptor complex, 913
 Receptor-selective opioids, 421
 Receptors, 27
 Recovery of function, 963
 Reinforcement, 107, 413
 Reinforcement value, 515
 Removable electrode, 993
 Renin-angiotensin system, 385
 Resistance to change, 515
 Response duration, 761
 Retrieval, 587
 Reverse tolerance, 603
 Reward, 515, 973
 Rhythm, 409
 Righting reflex, 739
 Risperidone, 553
 RN 72026-83-6, 255, 659
 Ro 15-4513, 147
 Route of administration, 487
 Rubidium, 409

 Saccharin, 307, 541, 547
 Saliva cotinine, 187
 Salt hunger, 617
 Salt intake, 609
 Sarthran, 385
 Satiety, 659
 SCH23390, 89, 101, 369, 749
 Schedule-controlled behavior, 421
 Schedule-induced alcohol consumption, 997
 Schedule-induced polydipsia, 393
 Schizophrenia, 141
 Scopolamine, 95
 Seizures, 241, 443
 Selected mouse lines, 443
 Selective breeding, 721
 Self-administration, 203, 795
 Self-stimulation, 803
 Sensitization, 13
 Sensitization, 203, 289, 345, 451, 559, 823
 Sequential behaviour, 647
 Serotonin, 59, 183, 467, 509, 547, 617

- Serotonin receptor antagonists, 575
 Serotonin_{1A} receptors, 467
 Serotonin₂ receptors, 467
 Serotonin, receptor, 59
 7-Chlorokynurenic acid, 241
 Sex differences, 265, 997
 Sexual behavior, 467, 771
 Sexual behaviour and orientation, 183
 Sexual differentiation, 183
 Sexual reflexes, 883
 Shuttle behavior, 219
 Shuttle box, 757
 Shuttlebox avoidance, 147
 6-OHDA, 345
 SK&F38393, 89
 Sleep, 359
 Sleep time, 351
 Smoked cocaine-base, 531
 Smokers, 107
 Smoking, 295
 Social behavior, 579
 Sodium appetite, 617
 S100, 647
 Spatial acquisition, 265
 Spatial discrimination test, 681
 Spatial learning, 95
 Spinal cord, 177
 Spiradoline, 487, 575
 Sprague-Dawley, 625
 Squirrel monkey(s), 421, 471
 Starvation, 215
 State-dependency, 951
 Stereoselectivity, 113
 Stereotypic behavior, 47
 Stereotypy, 603, 709, 827
 Steroids, 913
 Stimulus, 113
 Stimulus termination, 421
 Streptozotocin, 833
 Stress, 265, 393, 497, 617, 727, 913
 Stress-induced antinociception, 927
 Stress ulcers, 749
 Striatum, 33, 765
 Structure-activity relationship (SAR), 113
 Subjective effects, 295
 Suckling, 133
 Suckling maintenance, 133
 Sucrose, 73
 Sucrose intake, 515
 Sulpiride, 89, 749
 Supersensitivity, 141
 Synaptic remodelling, 647
 Synaptophysin, 647
 Tachykinin, 609
 Tachykinin receptors, 609
 Tacrine, 325
 Tail flick, 227, 301
 Tardive dyskinesia (TD), 141
 Taste, 73, 413
 Taste aversion, 73
 Taste aversion learning, 795
 Taste preference, 541
 Taste reactivity, 73, 413
 Temporal isolation, 65
 Testosterone, 591
 Tetrahydrocannabinol, 113
 TFMPP, 541
 THC, 33
 THC cue, 113
 Theta rhythm, 359
 3 α -Hydroxy-5 α -pregnan-20-one, 735
 Tiagabine, 5
 Time course study, 553
 T-maze, 951
 Tobacco smoking, 107
 Tolerance, 33, 171, 379, 451, 523, 567, 675, 739, 823
 Transmitter mediation, 121
 Tremor, 689
 TRH, 477
 Triazolam, 471
 Trichothecene mycotoxin, 363
 Trimethobenzamine, 273
 TRIMU-5, 943
 Two-bottle test for aversion, 659
 2-Deoxy-D-glucose, 317
 2-Thiazolyethylamine, 503
 2,3,7,8-Tetrachlorodibenzo-*p*-dioxin (TCDD), 273
 Tyrosine, 935
 Tyrosine hydroxylase, 47
 Ultralight cigarette, 187
 Ultrasonic vocalizations, 735
 Ultrasound, 947
 Unconditioned reflex, 289
 Urethrogenital reflexes, 883
 Valproic acid, 5
 Vasopressin, 587
 Vasopressin receptor antagonists, 27
 Ventral mesencephalon, 33
 Ventral striatum, 345
 Vigabatrin, 5
 Vomitoxin, 363
 Water intake, 255, 427, 659
 Water maze, 41
 Weanling rats, 247
 Withdrawal, 399, 633, 675, 919
 Within-session effects, 761
 Working memory, 325, 935
 WSP, 443
 WSR, 443
 Xylamidine, 547
 YM-09151-2, 101
 Zolpidem, 359
 Zucker, 625

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR

VOLUME 47 1994

AUTHOR INDEX

- Absil, P., 77
 Agmo, A., 771
 Aguilar, M. A., 753
 Ahlenius, S., 509
 Airaksinen, M. M., 681
 Akiyama, K., 161
 Albonetti, E., 591
 Allen, M., 827
 Anderson, K., 997
 Andersson, G., 947
 Andrade, M., 467
 Anisman, H., 497
 Aravich, P. F., 215
 Atrens, D. M., 369
 Aulakh, C. S., 985

 Baars, A. M., 27
 Babbini, M., 969
 Babu, S. R., 779
 Bacchi, A., 969
 Baker, R. C., 721
 Balster, R. L., 5
 Balthazart, J., 77
 Barber, D. J., 541
 Bartoletti, M., 969
 Bättig, K., 187
 Bauer, A., 857
 Bellinger, L. L., 255, 659
 Bernardis, L. L., 247
 Bernstein, H.-G., 587
 Beverly, M., 857
 Beyer, C., 177
 Billington, C. J., 317
 Binkerd, K., 547
 Blanco, M. E., 493
 Block, A. K., 795
 Blokland, A., 833
 Blosser, J. C., 701
 Bodnar, R. J., 727
 Bole-Vunduk, B., 301
 Booij, L. H. D. J., 21
 Borg, P. J., 633
 Borsini, F., 95
 Boulos, Z., 471
 Bowen, S. E., 761
 Brambilla, A., 95
 Bratton, G. R., 227
 Brauer, L. H., 531
 Breen, L., 233
 Broder, L., 617
 Brown, J., 675
 Brunelli, S. A., 735
 Buckenmeyer, P. J., 779
 Bunker, E. B., 919
 Burkey, R. T., 227
 Butterworth, A. R., 675

 Caba, M., 177

 Caldarola-Pastuszka, M., 467
 Cancela, L. M., 789
 Cannon, D. S., 795
 Carretta, J. C., 515
 Cavoy, A., 283
 Chakravarti, A. K., 749
 Chan, A. W. K., 567
 Chojnacka-Wójcik, E., 873
 Chow, S., 375
 Christie, M. J., 369
 Ciccocioppo, R., 609
 Cleary, J., 379
 Cleary, J. P., 317
 Cohen, C., 919
 Cole, B. J., 393
 Collins, A. C., 889
 Cooper, S. J., 541
 Correa-Sales, C., 171
 Cortizo, L., 509
 Crabbe, J., 443
 Crosby, R., 531

 Dajas, F., 1
 Darlington, C. L., 739
 Das, S., 77
 Davis, J. M., 989
 de Caro, G., 609
 de Costa, B. R., 715
 Deitrich, R. A., 721
 Delacour, J., 283
 Depoortere, H., 359
 Deutsch, S. I., 913
 de Wied, D., 27
 Diamant, M., 27
 Dirksen, R., 21
 Dokko, J. H., 617
 Domino, E. F., 603
 Dorow, J., 443
 Draski, L. J., 721
 Drucker, G. E., 141

 Eaton, R. C., 483
 Edwards, S., 865
 Eguchi, N., 689
 Eisenberg, R. M., 943
 Ellinwood, E. H., Jr., 399, 451
 Engel, J. A., 345
 Engh, K., 141
 Epstein, L. H., 107
 Escorihuela, R. M., 147

 Fahlke, C., 345
 Farabollini, F., 591
 Färkkilä, M., 901
 Ferko, A. P., 351
 Fernandes, C., 823
 Fernández-Ruiz, J. J., 33, 47
 Fernández-Teruel, A., 147

 Fields, J. Z., 141
 File, S. E., 823
 Filip, M., 873
 Fonte, C., 107, 295
 Fraioli, S., 339
 Frambes, N. A., 133
 Frankmann, S. P., 617
 Fujiwara, Y., 161

 Gaiardi, M., 969
 Galea, L. A. M., 265
 Garrett, B. E., 89
 Gauvin, D. V., 153
 Gelowitz, D. L., 41
 Ghoneim, M. M., 523
 Gietzen, D. W., 59
 Glasky, A. J., 325
 Glass, J., 531
 Glick, S. D., 765
 Gomez, M., 771
 Gonzalez, M. I., 183, 591
 González-Mariscal, G., 177
 Goodwin, G. A., 133
 Gordon, J. H., 141
 Gormezano, I., 523
 Gorriti, M. A., 33
 Gorzalka, B. B., 993
 Gottesmann, C., 359
 Graham, A. L., 857
 Grech, D. M., 5
 Griffiths, R. R., 981
 Grobe, J., 107
 Grobe, J. E., 295
 Groen, B., 879
 Grupp, L. A., 385
 Gubellini, C., 969
 Gunion, M. W., 207
 Guo, T.-Z., 171

 Hamann, S. R., 197
 Hamilton, J., 659
 Hansen, S., 345
 Hanson, K., 531
 Hård, E., 345
 Harding, S., 385
 Harford, R., 935
 Harvey, J. A., 289
 Hasenfratz, M., 187
 Hashim, A., 13
 Hashimoto, Y., 689
 Hatsukami, D. K., 531
 Hauger, R., 233
 Hayashi, T., 689
 Hayashi, Y., 171
 Hemby, S. E., 973
 Henningfield, J. E., 919
 Hernández, M. L., 47
 Heydari, N., 325

 Higgins, G. A., 307
 Hill, J. L., 985
 Himori, K., 219
 Hirst, M., 363
 Hitri, A., 913
 Hodge, C. W., 743
 Hofer, M. A., 735
 Hoffman, D. C., 907
 Hokkanen, L., 901
 Holloway, F. A., 153
 Holm, S., 427
 Holtzman, S. G., 89, 421, 487, 559, 575
 Houpt, T. A., 471
 Huang, X., 667
 Hubert, G. W., 973
 Hull, E. M., 483
 Hulse Neufeld, J., 233
 Hurt, W. D., 845

 Iinuma, K., 503
 Ijaz, S., 963
 Irzabal, Y., 771

 Jackson, D. E., 761
 Jackson, D. M., 369
 Jacober, A., 187
 Jaffe, K., 493
 Järbe, T. U. C., 113
 Javadi, J. I., 989
 Jiang, J. C., 59
 Johnson, D. W., 765
 Jolles, J., 833
 Jones, D. N. C., 421
 Jones, G. H., 973
 Jørgensen, O. S., 647
 Joyner, C., 451
 Joyner, C. M., 399
 Justice, J. B., Jr., 973

 Kaczmarek, L., 757
 Kaminski, B. J., 981
 Kanzaki, A., 161
 Karanth, K. S., 951
 Katz, J. L., 709
 Kavaliers, M., 265
 Kawanishi, K., 689
 Keller, E. A., 789
 Khan, A., 477
 Kido, H., 553
 King, G. R., 399, 451
 Kinsley, C. H., 857
 Kitchen, I., 927
 Klauenberg, B. J., 845
 Klemfuss, H., 409
 Klint, T., 947
 Knowlton, R. G., 779
 Ko, J., 375

- Koob, G. F., 393, 819
 Kovács, A., 121
 Kovács, G. L., 27
 Kowalski, K., 935
 Kripke, D. F., 409
 Krisch, I., 301
 Kruse, C. B., 515
 Kumar, K. B., 951
 Kuribara, H., 101

 Lai, C.-T., 41
 Lai, H., 477
 Lajtha, A., 13
 Lê, A. D., 375
 Leeb, K., 413
 Leeka, J. K., 795
 Leret, M. L., 183
 Levine, A. S., 317
 Lin, H. Q., 369
 Little, H. J., 675
 Lumley, L. A., 483

 Macenski, M. J., 379
 Markowski, V. P., 483
 Marona-Lewicka, D., 667
 Marson, L., 883
 Martin, W. R., 197
 Massi, M., 609
 Maswood, S., 467
 Maze, M., 171
 McGregor, I. S., 369
 McKenna, K. E., 883
 McLaurin, B. I., 827
 Mechoulam, R., 113
 Medina, J. H., 1
 Mehta, A. K., 355
 Melchior, C. L., 325, 437
 Mendel, V. E., 255
 Merritt, J. H., 845
 Meyer, Melissa E., 827
 Meyer, Merle E., 827
 Miñarro, J., 753
 Mirolo, M. H., 477
 Mishima, K., 219
 Mogensen, J., 427, 647
 Molina, V. A., 789
 Moody, C. A., 133
 Moon, Y., 523
 Mori, H., 553
 Morley, J. E., 207
 Moses, J., 483
 Muhammad, B. Y., 927
 Murphy, D. L., 985

 Nacif-Coelho, C., 171
 Nagy, J., 659
 Nation, J. R., 227
 Navarro, M., 47
 Neill, D. B., 973
 Nelson, R., 531

 Nencini, P., 339
 Nichols, D. E., 667
 Niemi, M.-L., 901
 Nieminen, S. A., 681
 Nikolaev, E., 757
 Núñez, J. F., 147

 Olds, M. E., 803
 Olivier, B., 957
 Onodera, K., 503
 Orłowski, M., 715
 Orsingher, O. A., 789
 Ossenkopp, K.-P., 265, 363

 Paladini, A., 1
 Palomo, T., 33
 Pandey, S. C., 989
 Papanikolaou, A., 579
 Park, C. H., 913
 Parker, L., 413
 Parker, L. A., 73
 Pedersen, S. L., 647
 Pedersen, T. K., 427
 Peirce, J. M., 153
 Pentel, P. R., 531
 Pérez-Iranzo, N., 753
 Perkins, K. A., 107, 295
 Peterson, S. L., 241
 Petrov, E. S., 715
 Pfaff, R. C., 667
 Philippens, I. H. C. H. M., 879
 Pickworth, W. B., 919
 Pirzadeh, B., 325
 Pitsikas, N., 95
 Poeggel, G., 587
 Pohjanvirta, R., 273
 Polidori, C., 609
 Pollak, C. P., 65
 Pompei, P., 609
 Poulos, C. X., 307
 Poutiainen, E., 901
 Prunell, M., 147
 Przeglasiński, E., 873
 Pulvirenti, L., 819
 Puri, S., 749

 Quan, B., 375
 Quock, R. M., 845

 Rabbani, M., 675
 Railoma, O., 681
 Ramalingam, S., 951
 Ramos, J. A., 33, 47
 Rapley, W. A., 363
 Ray, A., 749
 Reid, K., 171
 Reiser, M., 587
 Renton, C., 497
 Reynolds, W. A., 295

 Rice, K. C., 715
 Richardson, J. S., 41
 Richardson, S. A., 331
 Rieg, T. S., 215
 Ritzmann, R. F., 141, 325, 437
 Robinson, S. R., 715
 Rodríguez de Fonseca, F., 33, 47
 Romano, A. G., 289
 Rosamond, J. R., 701
 Rossi, R., 851

 Sakamoto, H., 553
 Saksida, L., 265
 Salamone, J. D., 579
 Schaal, D. W., 317, 379
 Scharrer, E., 851
 Schenk, S., 203
 Schmidt, W. K., 487
 Schrot, J., 935
 Schuh, K. J., 317
 Schulze, H. G., 993
 Schwarzberg, H., 587
 Scott, S. J., 739
 Seidleck, B. K., 839
 Sellers, E. M., 307
 Sen, P. A., 749
 Sershen, H., 13
 Sexton, J. E., 295
 Shanks, N., 497
 Sharpe, L. G., 709
 Shiba, K., 553
 Shuaib, A., 963
 Shurtleff, D., 935
 Simmons, R. D., 701
 Simón, V. M., 753
 Slangen, J. L., 957
 Smith, G. P., 617
 Smith, P. F., 739
 Smotherman, W. P., 715
 Sokolowski, J. D., 579
 Soliman, K. F. A., 625
 Somani, S. M., 779
 Spear, L. P., 133
 Spinella, M., 727
 Sprague, J. E., 547
 Starr, B. S., 127
 Starr, M. S., 127
 Steinfels, G. F., 487, 575
 Steinman, J. L., 207
 Steinpreis, R. E., 579
 Stevens, R., 865
 Stiller, R. L., 295
 Stino, F. K. R., 625
 Stout, J. C., 459
 Sumiyoshi, T., 553
 Suzuki, K., 553
 Székely, J. I., 709

 Tatarczyńska, E., 873

 Taylor, D. A., 633
 Telegdy, G., 121
 Thomas, J. R., 935
 Thompson, T., 317, 379
 Thurkauf, A., 839
 Ticku, M. K., 355
 Titievsky, A. V., 681
 Tizabi, Y., 331
 Tobeña, A., 147
 Tomkins, D. M., 307
 Trefouret, S., 359
 Tsuchida, K., 161
 Tuomisto, J., 273
 Turco, D., 857

 Uchihashi, Y., 101
 Ujike, H., 161
 Ukai, Y., 477
 Unkila, M., 273
 Uphouse, L., 467
 Urasaki, K., 553

 Valadez, A., 203
 Van De Kamp, J. L., 889
 Van Diejen, D., 21
 Van Golf-Racht, B., 283
 van Haaren, F., 997
 Van Liew, J. B., 247
 van Luijtelaar, E. L. J. M., 21
 Varlinskaya, E. I., 715
 Vigorito, M., 515
 Viola, H., 1

 Wadenberg, M.-L., 509
 Wagner, D. R., 65
 Watanabe, T., 503
 Weiss, J. M., 459
 Wellman, J., 857
 White-Gbadebo, D., 559
 Wichlinski, L. J., 141
 Wilson, C. A., 591
 Wishart, T. B., 41, 963
 Witkin, J. M., 839
 Wolfman, C., 1
 Wolthuis, O. L., 879

 Xu, X., 603

 Yamaguchi, N., 553
 Ybema, C. E., 957
 Yokogawa, K., 553
 Yokoyama, H., 503
 York, J. L., 567
 Young, E. R., 443
 Yu, P. H., 41

 Zabik, J. E., 547
 Zahalka, J., 113
 Zalcman, S., 497
 Zimmerberg, B., 735